FIGO staging of endometrial cancer: 2023

INTRODUCTION: Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. METHODS: The FIGO Women\u27s Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system. RESULTS: Based on the existing evidence, the substages were defined as follows: SUMMARY: The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data

Should we modify the current FIGO staging system for stage IIIC ovarian cancer?

Ovarian cancer is the leading cause of death among female re-productive tract cancers and the fifth most common overall cause of cancer death among women, with 22,430 newly diag-nosed cases and 15,280 cause-specific deaths estimated in the United States in 2007.1 In Korea, it marks the eighth most common female cancer (3.6%) among 43,627 new total fe-male cancer cases, and cancer death (3.1%) among 24,014 cause-specific deaths.2 In 1983, Chen et al. reported the incidence of retro-peritoneal lymph node metastases in untreated cases of ovar-ian carcinoma. The incidence of positive para-aortic nodes i